Go to http://www.arthritisinsight.com/feature/acr2004/monday1.html for links
to the full articles and press releases.

Abbott Presents Promising Phase III Data for HUMIRA(R) (adalimumab) Plus
methotrexate as First-Line Treatment in Early Rheumatoid Arthritis
New Phase III findings to be presented at this week's annual meeting of the
American College of Rheumatology show that patients with early rheumatoid
arthritis (RA) experienced significant improvement in signs and symptoms while
taking HUMIRA® (adalimumab) in combination with methotrexate as a first-line
treatment. In addition, findings from a small, open-label, six-year extension
study assessing the safety and efficacy of HUMIRA also will be presented.

New Emerging Therapies for the Treatment of Lupus
Lupus treatments will be highlighted during a symposium at this year’s
American College of Rheumatology (ACR) annual scientific meeting in San
Antonio, TX. The symposium, “The Emerging Role of Antimetabolites in the
Treatment of Nonrenal Systemic Lupus Erythematosus (SLE),” will include
discussion of non-FDA approved agents under investigation for the treatment of
renal or nonrenal SLE.

Knee Pain Better Detected With Magnetic Resonance Imaging Than With X-rays
Clinicians treating patients with knee pain need to reconsider how they
evaluate patients -- perhaps using magnetic resonance imaging (MRI) rather than
x-rays to diagnose osteoarthritis (OA), researchers reported here at a press
conference today at the American College of Rheumatology 68th Annual Scientific
Meeting.

Phase III Clinical Trial Results Of Investigational Biologic Abatacept
Demonstrated Clinical Activity In Patients With Rheumatoid Arthritis
According to the results of two phase III clinical trials to be presented this
week at the annual meeting of the American College of Rheumatology (ACR), the
investigational biologic abatacept (ab-a-'ta-sept) -- a potential
first-in-class T-cell costimulation modulator discovered and developed by
Bristol-Myers Squibb Company -- demonstrated significant clinical activity in
patients with rheumatoid arthritis.

Promising Phase III Psoriatic Arthritis Data For HUMIRA(R) (adalimumab)
New Phase III study findings show that patients with active psoriatic arthritis
who had failed a previous non-steroidal anti-inflammatory drug (NSAID) therapy
achieved significant improvement in both joint and skin signs and symptoms
after treatment with Abbott's HUMIRA(R).

Stressful Imagery Evokes Altered Pain Perceptions in Women with Fibromyalgia
Compared to Healthy Subjects, says Study
Compared to healthy controls, people with fibromyalgia experience increased
pain sensitivity when exposed to psychosocial stressors, according to research
presented this week at the American College of Rheumatology (ACR) Annual
Scientific Meeting. Funded in part by the Arthritis Foundation, the studies
shed new light on understanding how people with fibromyalgia process pain.

Pneumococcal Vaccinations Prove Acceptable for Rheumatoid Arthritis Patients
Pneumococcal vaccinations help to protect patients with rheumatoid arthritis
against serious pneumococcal infections of the lungs, brain, blood, and ears ,
according to research presented this week at the American College of
Rheumatology Annual Scientific Meeting in San Antonio, Texas.

Patients with Knee Osteoarthritis May Benefit from Increased Levels of Vitamin
D
Higher levels of vitamin D appear to increase muscle strength, improving
physical function for knee-osteoarthritis patients who are vitamin-D deficient.